Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta.

Richa Jain,Amita Trehan,Prema Menon,Rakesh Kapoor,Nandita Kakkar,Srinivasan Radhika,Akshay Kumar Saxena,Bhagwant Rai Mittal,Neelam Varma,Ram Samujh,Deepak Bansal

Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta.

2021

Richa Jain
Amita Trehan
Prema Menon
Rakesh Kapoor
Nandita Kakkar
Srinivasan Radhika
Akshay Kumar Saxena
Bhagwant Rai Mittal
Neelam Varma
Ram Samujh
Deepak Bansal

The majority of patients with high-risk neuroblastoma (HR-NB) in low- and middle-income countries (LMIC) do not have access to autologous stem cell transplant (ASCT) and dinutuximab. Consolidation ...

Keywords:

high risk neuroblastoma
Medicine
Oncology
high dose chemotherapy
Dinutuximab
Dinutuximab beta
Neuroblastoma
Stem cell
in patient
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations